Probe Drugs for Botanical-Drug Interactions
Probe Drugs for Botanical-Drug Interactions
批准号:
7488440
负责人:
Gregory Allen Reed
金额:
$17.49万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-30 至 2010-08-31
关键词:
6-MercaptopurineAcuteAddressAffectAntidepressive AgentsBotanicalsBuspironeCYP1A2 geneCYP2C19 geneCYP2C9 geneCYP2D6 geneCYP3A4 geneCaffeineChronicCytochromesDesigner DrugsDevelopmentDextromethorphanDisciplineDoseDrug InteractionsDrug KineticsDrug PrescriptionsDrug usageEnzyme InductionEnzyme InhibitionEnzymesEuropeFMO3FutureGeneticGenetic MarkersGenetic PolymorphismGenomicsGenotypeGoalsHerbHumanHydrocortisoneHypericinHypericum perforatumIndividualKansasKetoconazoleLosartanMetabolismNAT2 geneNuclear ReceptorsOmeprazoleOutcome StudyP-GlycoproteinPatientsPharmaceutical PreparationsPharmacogenomicsPharmacotherapyPhasePhase I Clinical TrialsPhenotypePlasmaProceduresPropertyPublic HealthRangeResearchSeriesSingle Nucleotide PolymorphismSpecimenStudy SubjectTestingUnited States National Institutes of HealthWarfarinbaseconstitutive androstane receptordata acquisitiondosagedrug efficacydrug metabolismenzyme activityfexofenadinehyperforininhibitor/antagonistpregnane X receptorprescription documentprescription procedureresponsetool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): St. John's Wort (SJW) is a widely used antidepressant. Both the antidepressant properties of SJW and its interactions with other drugs are related to its hyperforin content, not to hypericin. Hyperforin activates the Pregnane X Receptor (PXR), thereby inducing activities of drug metabolizing enzymes, cytochrome P450s (CYPs), and the transporter, P-glycoprotein (P-gp). Pharmacogenomics is a rapidly developing discipline whose objective is to customize drug therapy based on an individual's genotype. Thus far, the focus has been on adjusting doses of single drugs based on polymorphisms of drug metabolizing enzymes. As patients often take many drugs at once, our long term goal is to explore the genomics of pharmacokinetic (PK) drug interactions. Enhancement of drug metabolism by inducers varies by over 40 fold among individuals. We ultimately intend to explore genetic differences (Single Nucleotide Polymorphisms, SNPs) in CYPs and nuclear receptors (PXR, CAR [Constitutive Androstane Receptor], etc.) to develop genotype/phenotype relationships for individual responses to inducers. Probes are drugs used to study drug disposition. We have developed a probe drug cocktail that safely and conveniently probes for enzymes that metabolize and transport most clinically used drugs: caffeine (CYP1A2), losartan (CYP2C9), dextromethorphan (CYP2D6?also probes for CYP3A4), buspirone (CYP3A4), and fexofenadine (P-gp), in addition to cortisol, an endogenous CYPS A substrate. Initially, we propose to evaluate the feasibility of adding omeprazole to probe for CYP2C19 and for CYP3A4. (Multiple GYP3A4 substrates are desirable.) Then we will determine the ability of the probe drug cocktail to respond to enzyme inhibition and induction by SJW, using a product standardized to its hyperforin content. Initial genotyping of drug metabolizing enzymes and nuclear receptors will also be performed. Finally, we will determine if the drugs in the cocktail are susceptible to inhibition of metabolism by ketoconazole. The proposed studies will validate this well-tolerated probe cocktail for research into genomics of induction of enzymes by herbs like SJW. Development of such tools is a goal of the NIH Roadmap. We plan future use of these probes to look for human genomic markers to predict drug interactions. Relevance to public health: Saint John's wort, sold without prescription, affects the way that people respond to many prescription drugs. In addition, not all people are affected to the same extent. This project wjll test a procedure to better understand and predict the effects of Saint John's wort on prescription drugs in people.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Buspirone, fexofenadine, and omeprazole: quantification of probe drugs and their metabolites in human plasma.
丁螺环酮、非索非那定和奥美拉唑:人血浆中探针药物及其代谢物的定量。
DOI:
10.1016/j.jpba.2011.03.043
发表时间:
2011
期刊:
Journal of pharmaceutical and biomedical analysis
影响因子:
3.4
作者:
[Gor,Parul, Alnouti,Yazen, Reed,GregoryA]
通讯作者:
Reed,GregoryA
Quantification of the transporter substrate fexofenadine in cell lysates by liquid chromatography/tandem mass spectrometry.
通过液相色谱/串联质谱法对细胞裂解物中的转运蛋白底物非索非那定进行定量。
DOI:
10.1002/rcm.5111
发表时间:
2011
期刊:
Rapid communications in mass spectrometry : RCM
影响因子:
--
作者:
[Flynn,ColleenA, Alnouti,Yazen, Reed,GregoryA]
通讯作者:
Reed,GregoryA
Clinical Pharmacology Shared Resource
-
批准号:9975735
-
项目类别:
-
资助金额:$12.09万
-
财政年份:2012
-
负责人:Gregory Allen Reed
-
依托单位:
COBRE: U OF KANSAS MEDICAL CTR: ANALYTICAL CORE
-
批准号:8360783
-
项目类别:
-
资助金额:$11.29万
-
财政年份:2011
-
负责人:Gregory Allen Reed
-
依托单位:
COBRE: U OF KANSAS MEDICAL CTR: ANALYTICAL CORE
-
批准号:8167662
-
项目类别:
-
资助金额:$10.58万
-
财政年份:2010
-
负责人:Gregory Allen Reed
-
依托单位:
COBRE: U OF KANSAS MEDICAL CTR: CORE E: ANALYTICAL CORE
-
批准号:7959506
-
项目类别:
-
资助金额:$14.2万
-
财政年份:2009
-
负责人:Gregory Allen Reed
-
依托单位:
COBRE: U OF KANSAS MEDICAL CTR: CORE E: ANALYTICAL CORE
-
批准号:7720183
-
项目类别:
-
资助金额:$13.98万
-
财政年份:2008
-
负责人:Gregory Allen Reed
-
依托单位:
COBRE: U OF KANSAS MEDICAL CTR: CORE E: ANALYTICAL CORE
-
批准号:7610771
-
项目类别:
-
资助金额:$20.27万
-
财政年份:2007
-
负责人:Gregory Allen Reed
-
依托单位:
COBRE: U OF KANSAS MEDICAL CTR: CORE E: ANALYTICAL CORE
-
批准号:7382250
-
项目类别:
-
资助金额:$9.51万
-
财政年份:2006
-
负责人:Gregory Allen Reed
-
依托单位:
Probe Drugs for Botanical-Drug Interactions
-
批准号:7296133
-
项目类别:
-
资助金额:$17.84万
-
财政年份:2006
-
负责人:Gregory Allen Reed
-
依托单位:
Probe Drugs for Botanical-Drug Interactions
-
批准号:7101307
-
项目类别:
-
资助金额:$18.98万
-
财政年份:2006
-
负责人:Gregory Allen Reed
-
依托单位:
PULMONARY TOXICITY OF SULFUR DIOXIDE AND SULFITE
-
批准号:3252012
-
项目类别:
-
资助金额:$6.65万
-
财政年份:1987
-
负责人:Gregory Allen Reed
-
依托单位:
GENOTOXICITY OF BENZO[A]PYRENE DERIVATIVES AND SULFITE
-
批准号:2153561
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1987
-
负责人:Gregory Allen Reed
-
依托单位:
GENOTOXICITY OF BENZO[A]PYRENE DERIVATIVES AND SULFITE
-
批准号:3252011
-
项目类别:
-
资助金额:$10.12万
-
财政年份:1987
-
负责人:Gregory Allen Reed
-
依托单位:
PULMONARY TOXICITY OF SULFUR DIOXIDE AND SULFITE
-
批准号:3252013
-
项目类别:
-
资助金额:$6.89万
-
财政年份:1987
-
负责人:Gregory Allen Reed
-
依托单位:
GENOTOXICITY OF BENZO[A]PYRENE DERIVATIVES AND SULFITE
-
批准号:3252014
-
项目类别:
-
资助金额:$9.62万
-
财政年份:1987
-
负责人:Gregory Allen Reed
-
依托单位:
PULMONARY TOXICITY OF SULFUR DIOXIDE AND SULFITE
-
批准号:3252009
-
项目类别:
-
资助金额:$11.97万
-
财政年份:1987
-
负责人:Gregory Allen Reed
-
依托单位:
Clinical Pharmacology Shared Resource
-
批准号:9750032
-
项目类别:
-
资助金额:$11.86万
-
财政年份:--
-
负责人:Gregory Allen Reed
-
依托单位:
海外基金